Skip to main content
. 2020 Sep 11;13(9):242. doi: 10.3390/ph13090242

Figure 10.

Figure 10

(a) Design strategy of dual β-secretase (BACE-1)/ glycogen synthase kinase 3 (GSK-3β) inhibitors that combines the pharmacophoric features for the BACE-1 and GSK-3β binding; (b,c) chemical structures of the most promising derivatives. Adapted from [107].